pillbase.ru

Imlygic

Active substance: talimogene laherparepvec

talimogene laherparepvec

Centralised EU authorisationActive

Marketing holder: Amgen Europe B.V.

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 2
  • Imlygic
    INJECTION, SUSPENSION · TALIMOGENE LAHERPAREPVEC 1000000 [PFU]/mL
    55513-078
    Amgen Inc
  • Imlygic
    INJECTION, SUSPENSION · TALIMOGENE LAHERPAREPVEC 100000000 [PFU]/mL
    55513-079
    Amgen Inc
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-ed4c-7eae-b1cb-31e967647357,01a12098-d02f-786e-ba00-9754907bc8d4;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/002771
Registration status
Active
ATC code
L01XX51
Sources
  • product · EMA · EMEA/H/C/002771 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/002771 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/002771 · Verified 2026-10-09